A research team from UC San Francisco has discovered a previously unknown weakness in glioblastoma, one of the deadliest and hardest-to-treat types of brain cancer. Brain cancers usually originate from mutations in brain cells or the spinal cord, and they can be incredibly hard to treat due to their proximity to delicate and important brain tissue. Glioblastomas are an especially fast-growing and dangerous type of brain tumor that typically affects older adults and has no known cure. These tumors usually spread out to nearby brain cells, damaging and causing cognitive decline over time.
UC San Francisco researchers now say that this deadly encroachment of nearby brain cells could be the key to…
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.